The effect of bone marrow transplantation (BMT) on enzyme and glycosaminoglycan levels of various tissues and isolated parenchymal cells of lethally irradiated gusmPs/ gusmP" mice was studied. These mice have an inherited deficiency of the lysosomal enzyme P-glucuronidase with less than 1% of normal enzyme activity present in all tissues and represent a model of human mucopolysaccharidosis type VII. Tissues were evaluated 200 d after BMT and liver parenchymal cells 300 d after BMT. Normal levels of P-glucuronidase activities were present in spleen and peripheral blood leukocytes of gusmPs/gusmPs mice that underwent transplantations. Intermediate activities were found in lung (73%), kidney (4%), liver (lo%), heart (53%), muscle (55%), brain (6%), and liver parenchymal cells (10% of normal controls). A concomitant decrease in activity of the secondarily increased enzyme P-hexosaminidase was observed. BMT also led to a substantial reduction in storage of glycosaminoglycans in lung (130 to 100%), heart (350 to 106%), kidney (439 to 217%), brain (177 to 91%), liver (613 to 125%), and liver parenchymal cells (443 to 161% of normal controls). These findings were supported by elecThe use of BMT a s a form of enzyme replacement therapy for lysosomal storage diseases is based o n the idea that bone marrow from a healthy donor and the short-lived cells derived from bone marrow provide a permanent source of the missing enzyme (1). Enzyme 
tron microscopy. A normalization of the storage process was seen in the visceral organs spleen and liver and in the histiocytes of the heart. The kidney showed variable improvement depending on the cell type. In the brain, a substantial improvement of neuronal storage was observed, but BMT apparently had no effect on storage in glial cells. The subcellular localization of P-glucuronidase was investigated in liver parenchymal cells of mice that underwent transplantation. Subcellular fractionation provided evidence for a lysosomal localization of P-glucuronidase, indicating that transfer of P-glucuronidase of donor origin to the lysosomal compartment of parenchymal cells might at least partly be responsible for the observed decrease in storage of glycosaminoglycans in these cells. (5) . Once taken u p b y the cells, the normally functioning enzyme should reduce storage of specific metabolites inside the lysosome. Correction of the metabolic abnormality may result in clinical improvement. T h e first mechanism may be expected to be sufficient for clinical improvement only in those diseases that primarily affect the reticuloendothelial system such a s Gaucher's disease type I. The possible importance of the second mechanism is difficult t o evaluate at present, but the effect is obviously limited t o those tissues that contain bone marrow-derived tissue macrophages, s u c h a s spleen, liver, and lung. A s for the third mechanism, very little is known about the capacity of leukocytes and tissue macrophages to secrete lysosomal enzymes in vivo (6, 7) , and the contribution of these cells to the total circulating pool of lysosomal enzymes is unknown. Similarly, it is not known whether these secreted enzymes are of a form that can be efficiently taken up by other cell types.
Yet another mechanism could potentially lead to decreased storage in the tissues (8). If a concentration gradient of storage product exists between tissues and plasma, continuous clearance of storage product from the plasma pool by cells of donor origin would be expected to lead to decreased tissue levels of storage product. Studies in animal models are indispensable to gain insight into the displacement of host cells by donor cells and to study the uptake of lysosomal enzyme into cells not belonging to the reticuloendothelial system after BMT. A useful mouse model for MPS type VII was described some years ago (9). This mutant mouse, designated gusmPs/gusmPs, has an inherited deficiency of the lysosomal enzyme P-glucuronidase and has clinical and pathologic abnormalities comparable to those found in human MPS type VII (10) . Abnormal biochemical parameters associated with murine MPS VII include increased tissue GAG content and secondary elevations of several lysosomal enzymes including P-hexosaminidase. We have used this mouse model to study enzyme distribution and storage phenomena in tissues and isolated hepatocytes after long-term stable engraftment with syngeneic donor cells. The results of our biochemical and EM studies show that BMT leads to a substantial improvement in enzyme levels of P-glucuronidase and in storage of GAG in various tissues, including the brain, in the gusmPs/gusmPs mouse. Complete metabolic correction was observed in cells of hemopoietic origin, but the effect of BMT was not limited to these cells. Considerable improvement was also found in hepatocytes, neurons, and endothelial cells of the kidney. To test the hypothesis that P-glucuronidase originating from cells derived from donor hemopoietic cells actually reaches cells of nonhemopoietic origin, we performed studies with isolated liver parenchymal cells. The results of these experiments indicate transfer of P-glucuronidase of donor origin to the lysosomes of hepatocytes of the recipient gusmPs/gusmP" mice.
METHODS

Animals.
Breeding pairs carrying the mutant gusmPs gene ( C~. C -H -~~" ' / B~B~~-~U S~~" / + mice) were made available to us by Dr. Edward H. Birkenmeier (The Jackson Laboratory, Bar Harbor, ME). The mutation was transferred to a C57BIlRij background and the mutant strain was maintained by brother and sister matings using heterozygous mice. Affected (gusmPs/gusmP~), heterozygous, and normal mice were identified 3-5 d after birth by assaying the P-glucuronidase activity in clipped tails [sp act of gusmPs/gusmPs mice, 0.4 ? 0.2 (n = 30); heterozygotes, 27.4 ? 4.2 (n = 140); and normal mice, 57.1 -t 9.1 (n = 180) nmollmg proteinlh. The mice were maintained under specific pathogen-free conditions.
BMT. Bone marrow cells were obtained by flushing the femors and tibias of normal C57BIIRij donor mice with N-2-hydroxyethylpiperazine-N'-2-ethanesufonc acidbuffered Hanks' balanced salt solution. One d after lethal irradiation ('"Cs gamma rays, 8.5 Gy), lo7 nucleated bone marrow cells were injected into the tail vein of 60-d-old gusmPs/gusmPs recipient mice. This procedure leads to stable and complete engraftment with donor cells (11).
Biochemical analyses. Mutant mice (gusmPs/gusmps), mice that underwent transplantation (gusmPs/gusmPs + BMT), and normal mice were killed, and the various tissues were assayed for p-glucuronidase and P-hexosaminidase activities with fluorometric assays as described previously (1 1). Leukocytes were isolated after lysis of the red blood cells as described (12). Enzyme activities were determined in plasma, leukocytes, spleen, liver, lung, heart, muscle, kidney, and brain. GAG were quantitated with a dimethylene blue dye binding assay using a modification of the method of Farndale et al. (13) . Compared with the original procedure, the time of papain digestion of tissues was extended from 1 to 4 h. The incubation volume was 0.6 mL and the tissue protein concentration 20-30 mg/mL. After papain digestion, 0.2 mL of chloroform were added and the incubation mixture was vigorously mixed and briefly centrifuged at 10 000 x g to separate the phases. The GAG were determined in the clear supernatant. GAG content was expressed as pg of GAG per mg of protein. Protein was determined by the method of Lowry et al. (14) . Isolation of liver parenchymal cells. Liver parenchymal cells were isolated by collagenase treatment as described for rat liver by van Bezooyen et al. (15) and Seglen (16) with minor modifications to make the method suitable for mouse liver. The mice received an injection of anticoagulant [500 IU of Thromoboliquin (Organon Technica, Turnhout, Belgium) intraperitoneally] and were anesthetized with a mixture of three parts Aescoket (Aesculaap, Boxtel, The Netherlands), one part Rompun (Bayer, Leverkusen, Germany) (2%) (0.01 mL/10 g of body weight). The liver was perfused through the portal vein with ~a ' + -free perfusion medium (Hanks' balanced salt), pH 7.4, saturated with 95% oxygen-5% carbon dioxide for 15 min at 37°C with a flow rate of 1.2 mL/min using a 26-gauge needle. An incision in the inferior vena cava was made to discharge the perfusion fluid. Subsequently, a perfusion was performed with medium containing 0.05% (wtlvol) collagenase (type VIII; Sigma Chemical Co., St. Louis, MO) at a flow rate of 1.2 mL1min. The liver was removed, finely minced, and incubated for 5 min in medium containing in 0.05% (wtlvol) collagenase. The cell suspension was sieved through a 90-pm nylon filter and centrifuged for 1 min at 30 x g (without brake) to obtain a parenchymal cell pellet. The cells were resuspended twice in 5 mL of buffer and centrifuged again for 1 min at 30 x g . The pellet consisted of liver parenchymal cells and was essentially free of nonparenchymal cells (>95% pure) as judged by light microscopy after staining with hematoxylin and periodic acid-Schiff. The viability of these cells as measured with the trypan blue exclusion method was always >75% and in most cases >90%.
Subcellular fractionation of liver parenchymal cells. Immediately after isolation, the parenchymal cells were homogenized in ice-cold 0.25 M sucrose, 2 mM EDTA, 10 mM Tris-HCI, pH 7.4 (10% wt/vol), using a PotterElvehjem homogenizer. The homogenate was centrifuged for 10 min at 750 x g at 4°C. Of the resulting supernatant, 0.5 mL were mixed with 9 mL of 40% Percoll solution (Pharmacia, Uppsala, Sweden) and centrifuged for 20 min at 60 000 X g at 4°C using a TFT 75.13 rotor (Kontron, Zurich, Switzerland).
Fractions of 0.5 mL were collected from the bottom of the tube and assayed for P-glucuronidase activity and the following marker enzymes: P-hexosaminidase (lysos o m e~) , glucose-6-phosphatase (microsomes) (17) , and glutamate dehydrogenase (mitochondria) (18).
Analysis of urinary GAG. Urine was collected for 4 consecutive d. After dilution with water to a creatinine value of 1.25 mM, the pH was adjusted to 4.5 and the GAG were precipitated with 0.1% cetyltrimethylammonium bromide. Electrophoresis of the GAG was carried out as described (19).
EM studies. Tissues were fixed in 0.1 M phosphate buffer, pH 7.3, containing 1% glutaraldehyde and postfixed in 0.1 M phosphate buffer containing 1% osmium tetroxide. Standard procedures were used for epoxy resin embedding. Ultrathin sections were stained with uranyl acetate and lead citrate and examined in a Philips EM 400 electron microscope. 
RESULTS
P-Glucuronidase and P-hexosaminidase activities were measured in various tissues 200 d after BMT. The P-glucuronidase activity in leukocytes and spleen increased from almost undetectable to normal levels (Table l), confirming that the BMT procedure led to stable and complete engraftment. The secondarily increased enzyme P-hexosaminidase reverted to normal levels in these tissues (Table 2 ). In agreement with these findings, EM investigation of the spleen indicated complete reversal of the storage process in this tissue (Fig. 1) . Plasma P-glucuronidase activity rose to normal levels (Table I) , but the levels of P-hexosaminidase-although lower than in the untreated animals-remained consistently above normal (Table 2 ). Significant effects of BMT on P-glucuronidase activity were observed in lung (73%), heart (53%), and muscle (55% of normal controls) (Table 1) . Smaller effects were measured in kidney (4%), brain (6%), and liver (10% of normal controls) ( Table 1) . Concomitant with the increase in p-glucuronidase activity, a significant reduction in P-hexosaminidase activity from several times the normal level to levels slightly above normal was observed in all tissues (Table 2 ). These results partially confirm and extend those of previous studies in the gusmPs/gusmPs mouse (20) and in the C3H and B6H mouse, other models of low p-glucuronidase activity ( I 1, 21) .
The effect of BMT on the storage process was further investigated by measuring the levels of GAG in lung, heart, kidney, brain, and liver. Normalization or near normalization of the GAG levels was found in lung, heart, brain, and liver, whereas the GAG levels in kidney decreased from 540% to 220% of normal (Table 3 ). In support of the quantitative data, EM studies of the heart show a significant effect of BMT on the storage in tissue histiocytes (Fig. 2) . In brain, a significant effect on storage in neuronal cells of the cerebral cortex was observed, whereas the glial cells still seemed to be affected after Table 2 . Effect of BMT on P-herosaminidase activity (nmollmglli) in gu.~""'~'/g~s"'~'" mice * gusmp'/gusm"' Normal gusn'P'/gusm~' BMT (Fig. 3) . In liver, a completely normal appearance without vacuolation was seen in the Kupffer cells as well as in the parenchymal cells after BMT (Fig. 4) . In the kidney, the correction observed by EM was partial and varied with the cell type. A significant improvement to virtual normalization was seen in many endothelial cells lining the capillaries and the glomeruli (results not shown). The podocytes still showed extensive storage after BMT, although the content of the storage vacuoles in these cells after BMT differed from those of gusmPs/ gusmPS mice that did not undergo transplantation (Fig. 5) . Also, the tubular epithelial cells showed extensive storage in mice that did and mice that did not undergo transplantation, with more electron dense material present after BMT (results not shown). The effect of BMT on mesangial cells could not be evaluated with certainty. The urinary excretion of GAG completely normalized after BMT (Fig. 6) .
To study the effect of BMT on cells that are not of hemopoietic origin, the levels of P-glucuronidase, p-hexosaminidase, and GAG were measured in isolated hepatocytes. After BMT, P-glucuronidase activity was found to be present in these cells at about 10% of normal levels ( Table 4) . A reduction of P-hexosaminidase levels in hepatocytes was observed, but the activity remained significantly increased above normal. The levels of GAG were reduced after BMT to levels slightly above normal.
The subcellular localization of p-glucuronidase in hepatocytes was investigated by fractionation of a postnuclear supernatant on self-generating Percoll gradients. Figure 7a shows the distribution of p-glucuronidase and hexosaminidase in normal liver. Hepatocytes show a bimodal distribution of p-glucuronidase activity, in agreement with its lysosomal and microsomal localization (22). The activity cosedimented with the lysosomal marker hexosaminidase and with the microsomal marker glucose-6-phosphatase (fractions 14 and 15). A similar pattern was found after BMT in a normal mouse, showing that BMT per se did not affect the distribution of these enzymes in normal tissues (Fig. 76) . Figure 7c shows a shift of the lysosomal marker enzyme hexosaminidase in hepatocytes of affected gusmPs/gusmPs mice toward fractions of lower density. Apparently, storage lysosomes have a significantly lower density than normal lysosomes. p-Glucuronidase was completely absent. After BMT, the distribution of the lysosomal marker hexosaminidase showed a normal pattern (Fig. 7 d ) . This indicates a reversal of the storage process and confirms the EM findings presented in Figure 4 . The activity of p-glucuronidase closely followed the pattern of hexosaminidase, indicating its lysosomal localization (Fig. 7d) .
DISCUSSION
The normal values of P-glucuronidase in peripheral blood leukocytes and spleen, the normalization of the secondarily increased enzyme p-hexosaminidase in these tissues, and the complete disappearance of the storage vacuoles in spleen and Kupffer cells as shown by our EM findings confirm the importance of cell replacement in the process of metabolic correction by BMT in tissues that are rich in cells of hemopoietic origin. The increase of p-glucuronidase activity in lung and the reduction of p-hexosaminidase activity can also be at least partly explained by the presence of macrophages of hemopoietic origin in this tissue (23) . However, the effect of BMT was not limited to cells of the reticuloendothelial system. Also neurons, endothelial cells of the kidney, and hepatocytes showed considerable improvement after BMT. Two mechanisms that could possibly have contributed to the observed improvement in these cells are uptake by the cells of enzyme originating from bone marrow-derived cells of donor origin and continuous clearance of the GAG from the plasma pool by cells derived from the normal bone marrow. So far, direct evidence for enzyme replacement in cell types not belonging to the hemopoietic cell lineage has not been obtained. Our studies on isolated hepatocytes show that p-glucuronidase activity is present in the lysosomes of these cells in long-term stable engrafted gusmPs/gusmPs mice. This enzyme activity may have contributed to the normalization of lysosomal appearance observed by EM examination. The fact that p-hexosaminidase and GAG levels were still above control levels indicates that, despite the normal appearance of lysosomes, the storage process had not completely been reversed 300 d after BMT.
The mechanism by which p-glucuronidase actually reaches the lysosomal compartment of the hepatocytes is not clear. One possible explanation is that p-glucuronidase originating from cells of hemopoietic origin is shed into the circulation. The increase in circulating p-glucuronidase activity in plasma after BMT suggests that this does indeed occur. Subsequently, the enzyme may be taken up by hepatocytes, possibly by a receptormediated uptake mechanism, resulting in an increased activity of p-glucuronidase in the lysosomes of these cells. Alternatively, p-glucuronidase could be transferred from donor-derived Kupffer cells directly to neighboring hepatocytes. Earlier studies on tetraparental mice have provided evidence for intercellular transfer of p-glucuronidase in vivo in several tissues (24, 25) . In addition, transfer of p-glucuronidase from competent to deficient cells has been shown to occur in vitro between lymphocytes and fibroblasts in a mannose-6-phosphate receptorindependent way (3, 4). It is as yet impossible to distinguish between these two possible mechanisms, and it is conceivable that both mechanisms have contributed to the observed rise in p-glucuronidase activity in hepatocytes. A similar uptake mechanism could also be active in other cell types. This should lead to a lower total body burden of stored GAG, which may in turn contribute to improvement of the storage process that we have observed in cells of nonhemopoietic origin in liver, kidney, and brain.
In conclusion, we have shown that significant biochemical improvement in gusmPs/gusn'Ps mice is obtained by BMT under the condition of complete and stable engraftment. Both cell replacement and enzyme transfer are likely to have contributed to the observed effects. However, the effect of BMT was partial despite optimal conditions of long-term engraftment. It seems reasonable to expect a similar partial effect of BMT in human MPS VII. This may be sufficient to justify BMT in MPS VII patients with minimal CNS involvement. Allogeneic BMT in human patients requires a compatible donor, and the procedure is not without risk. Gene therapy by retrovirus-mediated gene transfer to a patient's own bone marrow stem cells would be an alternative. However, unless infected cells have an unexpected advantage (e.g. overexpressing the missing enzyme), this form of t h e r a p y is expected to be less efficient than BMT, inasmuch as only a fraction of the stem cells will be infected. This was recently shown in gene transfer experiments in the gusmPs/gusmPs mouse (26) . This calls for cautious optimism with respect to the application of these forms of therapy for MPS storage diseases and suggests that alternative forms of therapy such as enzyme therapy should be vigorously pursued.
